AMERICAN DENTAL LASER AND SUNRISE TECHNOLOGIES RECEIVE AUTHORIZATION TO DO HUMAN CLINICAL TRIALS WITH LASER ON TOOTH DECAY
AMERICAN DENTAL LASER AND SUNRISE TECHNOLOGIES RECEIVE AUTHORIZATION
TO DO HUMAN CLINICAL TRIALS WITH LASER ON TOOTH DECAY
TROY, Mich., Nov. 4 /PRNewswire/ -- American Dental Laser (NASDAQ: ADLI) and Sunrise Technologies (NASDAQ: SNRS) announced today that the U.S. Food & Drug Administration has authorized human clinical trials on tooth decay with their Nd:YAG laser.
The trials will begin immediately according to Daniel S. Goldsmith, president and chief executive officer of American Dental Laser.
"This is a significant step forward in our effort to obtain FDA clearance to market our laser for use on teeth. The laser is used for dental procedures on teeth in 16 other countries," Goldsmith said.
"American Dental Laser believes that this is the first FDA authorization to begin human clinical trials with a dental laser for the treatment of cavities," Goldsmith added.
This pulsed Nd:YAG laser is currently used for soft tissue applications such as gum surgery, often without anesthesia. The laser allows dentists to have precise control when performing dental procedures with a significant reduction in bleeding and less destruction of healthy tissue.
Currently, the Nd:YAG laser is used by hundreds of dentists in the United States for gum treatment. More than 500,000 patients outside the United States have been treated effectively with the laser for both gum and tooth problems.
American Dental Laser, headquartered in Troy, Mich., is the largest developer, marketer and distributor of dental lasers in the world. The Nd:YAG dental laser is manufactured by Sunrise for American Dental Laser.
/CONTACT: Eric Fris, chief financial officer, 313-637-3713, or Marilynn Doll (media), 313-637-3753, both of American Dental Laser/
(ADLI SNRS) CO: American Dental Laser; Sunrise Technologies ST: Michigan IN: MTC SU: JT -- NY007 -- 0549 11/04/91 08:01 EST